Gomiliximab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** IDEC-152 was developed to decrease the body's response to allergens, thereby affecting diseases related to asthma and allergic disorders. This chimeric monoclonal antibody binds to the CD23 receptor, by which IDEC-152 may favorably influence asthma through its selective regulation of IgE production and its inhibition of other inflammatory pathways.

**Synonyms:** - GOMILIXIMAB - Lumiliximab - Monoclonal Antibody IDEC-152 - anti-CD23 Antibody - p5E8